Zymeworks Aktie

19,30 EUR -0,50 EUR -2,53 %

20.02.2026

BMN

22,70 USD -0,59 USD -2,53 %

nachbörslich20.02.2026

BTT

Zymeworks jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.1,50 Mrd. EUR

Div. Rendite0,00%

WKNA3DSSN

ISINUS98985Y1082

SymbolZYME

Zymeworks Aktien News

Sortieren:Datum Meistgelesen

30.05.25GlobeNewswireZymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

22.05.25GlobeNewswireZymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

21.05.25GlobeNewswireZymeworks Announces Participation in Upcoming Investor Conferences

WerbungZymeworks-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

19.05.25GlobeNewswireZymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

25.04.25GlobeNewswireZymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

21.04.25GlobeNewswireZymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

26.03.25GlobeNewswireZymeworks Announces Participation in Upcoming Investor Conferences

25.03.25GlobeNewswireZymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

26.02.25GlobeNewswireZymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

25.02.25GlobeNewswireZymeworks Announces Participation in Upcoming Investor Conferences

13.02.25GlobeNewswireZymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

30.01.25GlobeNewswireZymeworks Announces Participation in Upcoming Investor Conferences

08.01.25GlobeNewswireZymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

12.12.24GlobeNewswireZymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

21.11.24GlobeNewswireZymeworks Announces Participation in Upcoming Investor Conferences

21.11.24GlobeNewswireFDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

29.10.24GlobeNewswireZymeworks Announces Participation in Upcoming Investor Conferences

25.10.24GlobeNewswireZymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

21.10.24GlobeNewswireZymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

18.09.24GlobeNewswireZymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

22.08.24GlobeNewswireZymeworks Announces Participation in Upcoming Investor Conferences

01.08.24GlobeNewswireZymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock

25.07.24GlobeNewswireZymeworks Appoints Leone Patterson as Chief Business and Financial Officer

11.07.24GlobeNewswireZymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

17.06.24GlobeNewswireZymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

10.06.24GlobeNewswireZymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

28.05.24GlobeNewswireZymeworks Announces Participation in Upcoming Investor Conferences

07.05.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

02.05.24GlobeNewswireZymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results

30.04.24GlobeNewswireZymeworks Announces Participation in Upcoming Investor Conferences

28.04.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

20.04.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

08.04.24GlobeNewswireZymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

28.03.24GlobeNewswireZymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

27.03.24GlobeNewswireZymeworks Announces Participation in Upcoming Investor Conferences

05.03.24GlobeNewswireZymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting

27.02.24GlobeNewswireZymeworks Announces Participation in Upcoming Investor Conferences

08.02.24GlobeNewswireZymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

31.01.24GlobeNewswireZymeworks Announces Participation in Upcoming Investor Conferences

04.01.24GlobeNewswireZymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025

Zymeworks News

Zymeworks News: auf dieser Seite finden Sie alle Zymeworks News und Nachrichten zur Zymeworks Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Zymeworks News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Zymeworks News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.